Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001753763-18-000001
Filing Date
2018-09-24
Accepted
2018-09-24 19:07:35
Documents
1
Period of Report
2018-09-13

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 3  
1 PRIMARY DOCUMENT primary_doc.xml 3 5244
  Complete submission text file 0001753763-18-000001.txt   6725
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 5251 DTC PARKWAY, SUITE 285 GREENWOOD VILLAGE CO 80111
Business Address
Scott John K Jr. (Reporting) CIK: 0001753763 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35076 | Film No.: 181084397